CTLA4 and lung carcinoma: Seeing as lung cancers are commonly treated with ipilimumab, a CTLA-4 inhibitor, it remains unclear whether cancer type or ICI regimen plays a larger role in increasing the risk of neuro-ophthalmic irAEs [36].